Evidence map›Paper›PMID 36757183›Full record

ArticleJournal of clinical microbiology2023

Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort.

Rehan R Syed, Donald G Catanzaro, Rebecca E Colman, Christopher G Cooney, Yvonne Linger, Alexander V Kukhtin, Rebecca C Holmberg, Ryan Norville, Valeriu Crudu, Nelly Ciobanu and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Whole-Genome Sequencing to PredictAntibiotics (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Rehan R Syed *Department of Medicine, University of California, San Diego, La Jolla, California, USA.ORCID 0000-0001-8898-7388
Donald G Catanzaro *Department of Biological Sciences, University of Arkansas, Fayetteville, Arkansas, USA.ORCID 0000-0003-1760-0574
Rebecca E ColmanDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.ORCID 0000-0002-6854-2100
Christopher G CooneyAkonni Biosystems, Inc., Frederick, Maryland, USA.
Yvonne LingerAkonni Biosystems, Inc., Frederick, Maryland, USA.
Alexander V KukhtinAkonni Biosystems, Inc., Frederick, Maryland, USA.
Rebecca C HolmbergAkonni Biosystems, Inc., Frederick, Maryland, USA.
Ryan NorvilleAkonni Biosystems, Inc., Frederick, Maryland, USA.
Valeriu CruduPhthisiopneumology Institute, Chișinău, Republic of Moldova.
Nelly CiobanuPhthisiopneumology Institute, Chișinău, Republic of Moldova.
Alexandru CodreanuPhthisiopneumology Institute, Chișinău, Republic of Moldova.
Marva SeifertDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.ORCID 0000-0002-7554-6396
Naomi HilleryHerbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, California, USA.
Peter ChilesDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.
Antonino CatanzaroDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.
Timothy C RodwellDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.
University of California San Diego · USAkonni Biosystems (United States) · USPhthisiopneumology Institute "Chiril Draganiuc" · MDUniversity of Arkansas at Fayetteville · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
HOPE Training GrantT32AI007384 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Sara Gianella Weibel, Scott L Letendre · 1990 to 2026
$9.7M
An Integrated Tabletop Platform for Rapid Detection of XDR-TB in Clinical SamplesR01AI111435 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RODWELL, TIMOTHY CHARLES · 2014 to 2018
$5.4M
TB Diagnostics at the Point of CareR44AI138903 · NIAID · AKONNI BIOSYSTEMS, INC. · PI COONEY, CHRISTOPHER GERARD · 2018 to 2020
$3.0M
A low-cost instrument for nucleic acid isolation.R44GM103053 · NIGMS · AKONNI BIOSYSTEMS, INC. · PI CHANDLER, DARRELL P, COONEY, CHRISTOPHER GERARD · 2015 to 2016
$1.5M
TB Diagnostics at the Point of CareR44EB011274 · NIBIB · AKONNI BIOSYSTEMS, INC. · PI COONEY, CHRISTOPHER GERARD · 2013 to 2015
$1.2M
Culture-free next generation sequencing for rapid detection of drug-resistant tuberculosisR21AI135756 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RODWELL, TIMOTHY CHARLES · 2018 to 2019
$500k
NCATS NIH HHS UL1 TR001442NIAID NIH HHS HHSN272201600024CNIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI111435NIAID NIH HHS R21 AI135756NIAID NIH HHS R44 AI138903NIAID NIH HHS T32 AI007384NIBIB NIH HHS R44 EB011274NIGMS NIH HHS R44 GM103053
6 · The paper itself

Abstract

While the goal of universal drug susceptibility testing has been a key component of the WHO End TB Strategy, in practice, this remains inaccessible to many. Rapid molecular tests for tuberculosis (TB) and antituberculosis drug resistance could significantly improve access to testing. In this study, we evaluated the accuracy of the Akonni Biosystems XDR-TB (extensively drug-resistant TB) TruArray and lateral-flow-cell (XDR-LFC) assay (Akonni Biosystems, Inc., Frederick, MD, USA), a novel assay that detects mutations in seven genes associated with resistance to antituberculosis drugs:

Indexed as

Extensively Drug-Resistant TuberculosisMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAmikacinAntitubercular AgentsBacterial ProteinsCapreomycinDrug Resistance, Multiple, BacterialFluoroquinolonesHumansIsoniazidKanamycinMicrobial Sensitivity TestsProspective StudiesRifampinAmikacinAntitubercular AgentsBacterial ProteinsCapreomycinFluoroquinolonesIsoniazidKanamycinRifampinamikacincapreomycindrug-resistant tuberculosisdrug susceptibilityfluoroquinoloneisoniazidkanamycinlateral-flow cellMycobacterium tuberculosisrifampin

Identifiers

PMID36757183
PMCPMC10035299
OpenAlexW4319656019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.